Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2017

01-01-2017 | Preclinical study

Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells

Authors: Michael W. Daniels, Guy N. Brock, James L. Wittliff

Published in: Breast Cancer Research and Treatment | Issue 2/2017

Login to get access

Abstract

Purpose

Certain peptide hormones and/or their cognate receptors influencing normal cellular pathways also have been detected in breast cancers. The hypothesis is that gene subsets of these regulatory molecules predict risk of breast carcinoma recurrence in patients with primary disease.

Methods

Gene expression levels of 61 hormones and 81 receptors were determined by microarray with LCM-procured carcinoma cells of 247 de-identified biopsies. Univariable and multivariable Cox regressions were determined using expression levels of each hormone/receptor gene, individually or as a pair.

Results

Molecular signatures for ER+/PR+, ER−/PR−, and ER− carcinoma cells deciphered by LASSO were externally validated at HRs (CI) of 2.8 (1.84–4.4), 1.53 (1.01–2.3), and 1.72 (1.15–2.56), respectively. Using LCM-procured breast carcinoma cells, a 16-gene molecular signature was derived for ER+/PR+ biopsies, whereas a 10-gene signature was deciphered for ER−/PR− cancers. Four genes, POMC, CALCR, AVPR1A, and GH1, of this 10-gene signature were identified in a 6-gene molecular signature for ER− specimens.

Conclusions

Applying these signatures, Kaplan–Meier plots definitively identified a cohort of patients with either ER−/PR− or ER− carcinomas that exhibited low risk of recurrence. In contrast, the ER+/PR+ signature identified a cohort of patients with high risk of breast cancer recurrence. Each of the three molecular signatures predicted clinical outcomes of breast cancer patients with greater accuracy than observed with either single-gene analysis or by ER/PR protein content alone. Collectively, our results suggest that gene expression profiles of breast carcinomas with suspected poor prognosis (ER−/PR−) have identified a subset of patients with decreased risk of recurrence.
Appendix
Available only for authorised users
Literature
1.
Fisher B, Redmond C, Brown A, Wickerham D, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittliff J (1983) Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1(4):227–241CrossRefPubMed
2.
Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305(1):1–6CrossRefPubMed
3.
Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff JL (2002) Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche H, Schwartz MK, Chan DW (eds) Tumor markers: physiology, pathobiology, technology and clinical applications. AACC, Chicago, pp 33–63
4.
Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):e48–e72PubMed
5.
Wittliff J, Pasic R, Bland K (1998) Steroid and peptide hormone receptors: methods, quality control and clinical use. In: Bland KI, Copeland EM III (eds) The breast: comprehensive management of benign and malignant diseases, 2nd edn. WB Saunders Co, Philadelphia, pp 458–498
6.
7.
DeSombre ER, Carbone PP, Jensen EV, McGuire WL, Wells SA Jr, Wittliff JL, Lipsett MB (1979) Special report. Steriod receptors in breast cancer. N Engl J Med 301(18):1011–1012CrossRefPubMed
8.
Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43PubMed
9.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684CrossRefPubMed
10.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefPubMed
11.
Gingras I, Desmedt C, Ignatiadis M, Sotiriou C (2015) CCR 20th anniversary commentary: gene-expression signature in breast cancer—where did it start and where are we now? Clin Cancer Res 21(21):4743–4746CrossRefPubMed
12.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752CrossRefPubMed
13.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685CrossRefPubMed
14.
Wittliff J, Ma X, Stecker K, Salunga R, Tuggle J, Tran Y, Mesina K, Payette T, McQuary P, Pistone M (2002) Gene expression profiles and tumor marker signatures of human breast carcinoma cells procured by laser capture microdissection. Endocrine Soc Abs 3:538
15.
Ben-David M, Kadar T, Wittliff J, Biran S, Schally A (1987) Characterization of prolactin receptors and their distribution among American and Israeli women with breast cancer: implications for prediction of hormonal dependency and treatment. Biomed pharmacother 42(2):101–109
16.
Fekete M, Wittliff JL, Schally AV (1989) Characteristics and distribution of receptors for [d-trp6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3(3):137–147CrossRefPubMed
17.
Halmos G, Wittliff JL, Schally AV (1995) Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 55(2):280–287PubMed
18.
19.
20.
Chen A, Kaganovsky E, Rahimipour S, Ben-Aroya N, Okon E, Koch Y (2002) Two forms of gonadotropin-releasing hormone (GnRH) are expressed in human breast tissue and overexpressed in breast cancer a putative mechanism for the antiproliferative effect of GnRH by down-regulation of acidic ribosomal phosphoproteins P1 and P2. Cancer Res 62(4):1036–1044PubMed
21.
Falzon M, Du P (2000) Enhanced Growth of MCF-7 breast cancer cells overexpressing parathyroid hormone-related peptide 1. Endocrinology 141(5):1882–1892PubMed
22.
Norman AW, Henry HL (2014) Hormones. Elsevier Science, Amsterdam
23.
Pierce JG (1982) Protein and peptide hormones. Hutchinson Ross Pub Co, Stroudsburg
24.
Andres SA, Bickett KE, Alatoum MA, Kalbfleisch TS, Brock GN, Wittliff JL (2015) Interaction between smoking history and gene expression levels impacts survival of breast cancer patients. Breast Cancer Res Treat 152(3):545–556CrossRefPubMed
25.
Andres SA, Brock GN, Wittliff JL (2013) Interrogating differences in expression of targeted gene sets to predict breast cancer outcome. BMC Cancer 13(1):1CrossRef
26.
Andres SA, Wittliff JL (2011) Relationships of ESR1 and XBP1 expression in human breast carcinoma and stromal cells isolated by laser capture microdissection compared to intact breast cancer tissue. Endocrine 40(2):212–221CrossRefPubMed
27.
Andres SA, Wittliff JL (2012) Co-expression of genes with estrogen receptor-α and progesterone receptor in human breast carcinoma tissue. Horm Mol Biol Clin Investig 12(1):377–390PubMed
28.
Andres SA, Wittliff JL (2012) Co-expression of genes with estrogen receptor-alpha and progesterone receptor in human breast carcinoma tissue. Horm Mol Biol Clin Investig 12(1):377–390PubMed
29.
Ma X, Wang W, Salunga R, Tuggle T, Stecker K, Baer T, Erlander M, Wittliff J (2003) Gene expression signatures associated with clinical outcome in breast cancer via laser capture microdissection. Breast Cancer Res Treat 82:S15
30.
Andres SA, Wittliff JL, Cheng A (2013) Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status. Horm Cancer 4(4):208–221CrossRefPubMed
31.
Kerr DA II, Wittliff JL (2011) A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen. Horm Cancer 2(5):261–271CrossRefPubMed
32.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Statistics subcommittee of NCIEWGoCD: reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235CrossRefPubMed
33.
Kruer TL, Cummins TD, Powell DW, Wittliff JL (2013) Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior. Clin Biochem 46(16):1739–1746CrossRefPubMed
34.
El-Serag HB, Nurgalieva ZZ, Mistretta T-A, Finegold MJ, Souza R, Hilsenbeck S, Shaw C, Darlington G (2009) Gene expression in Barrett’s Esophagus: laser capture vs. whole tissue. Scand J Gastroenterol 44(7):787CrossRefPubMedPubMedCentral
35.
Greenspan FS, Gardner DG, Shoback D (1997) Basic and clinical endocrinology. Appleton & Lange, Stamford
36.
Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O’Carroll AM, Patel YC, Schonbrunn A, Taylor JE et al (1995) Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16(3):86–88CrossRefPubMed
37.
Spier AD, de Lecea L (2000) Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res Brain Res Rev 33(2–3):228–241CrossRefPubMed
38.
39.
Austin PC, Tu JV (2004) Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. J Clin Epidemiol 57(11):1138–1146CrossRefPubMed
40.
Goeman J, Meijer R, Chaturvedi N (2014) L1 and L2 penalized regression models. R package Version 0.9-45
41.
Goeman JJ (2010) L1 penalized estimation in the Cox proportional hazards model. Biometrical J 52(1):70–84
42.
43.
Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Pena JG, Trevino V (2013) SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE 8(9):e74250CrossRefPubMedPubMedCentral
44.
Lee YS, Challis BG, Thompson DA, Yeo GS, Keogh JM, Madonna ME, Wraight V, Sims M, Vatin V, Meyre D et al (2006) A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. Cell Metab 3(2):135–140CrossRefPubMed
45.
Cawley NX, Li Z, Loh YP (2016) 60 Years of POMC: biosynthesis, trafficking, and secretion of pro-opiomelanocortin-derived peptides. J Mol Endocrinol 56(4):T77–T97CrossRefPubMed
46.
McKenna NJ, Evans RM, O’Malley BW (2014) Nuclear receptor signaling: a home for nuclear receptor and coregulator signaling research. Nucl recept signal 12:e006PubMedPubMedCentral
47.
48.
Wittliff JL (1987) Molecular basis of endocrine-responsive cancers. Clin Physiol Biochem 5(3–4):160–178PubMed
49.
Blankenstein M, Maitimu-Smeele I, Donker G, Daroszewski J, Milewicz A, Thijssen J (1992) Tissue androgens and the endocrine autonomy of breast cancer. J Steroid Biochem Mol Biol 43(1–3):167–171CrossRefPubMed
50.
51.
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892CrossRefPubMedPubMedCentral
52.
Wittliff JL (2010) Laser capture microdissection and its use in genomics and proteomics, in reliable lab solutions. In: Conn PM (ed) Techniques in confocal microscopy. Elsevier, Amsterdam, pp 463–477
53.
Kerr A II, Eliason JF, Wittliff JL (2008) Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection. In: Li JJ et al (eds) Hormonal carcinogenesis V. Springer, Berlin, pp 377–384CrossRef
54.
Wittliff JL, Kunitake ST, Chu SS, Travis JC (2000) Applications of laser capture microdissection in genomics and proteomics. J Clin Ligand Assay 23(1):66–73
55.
Fedi P, Tronick SR, Aaronson SA (1997) Growth factors. In: Holland JF, Bast RC, Morton DL et al (eds) Cancer medicine. Williams & Wilkins, Baltimore, pp 41–64
56.
Bae YJ, Schaab M, Kratzsch J (2015) Calcitonin as biomarker for the medullary thyroid carcinoma. In: Raue F (ed) Medullary thyroid carcinoma. Springer, Berlin, pp 117–137CrossRef
57.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826CrossRefPubMed
58.
Nguyen B, Cusumano PG, Deck K, Kerlin D, Garcia AA, Barone JL, Rivera E, Yao K, de Snoo FA, van den Akker J (2012) Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol 19(10):3257–3263CrossRefPubMed
59.
Pelte MF, Schwaller J, Cerrato C, Meier CA (2004) Pro-opiomelanocortin expression in a metastatic breast carcinoma with ectopic ACTH secretion. Breast J 10(4):350–354CrossRefPubMed
60.
Perry JK, Emerald BS, Mertani HC, Lobie PE (2006) The oncogenic potential of growth hormone. Growth Hormon IGF Res 16(5):277–289CrossRef
61.
Wang X, Nakamura M, Mori I, Takeda K, Nakamura Y, Utsunomiya H, Yoshimura G, Sakurai T, Kakudo K (2004) Calcitonin receptor gene and breast cancer: quantitative analysis with laser capture microdissection. Breast Cancer Res Treat 83(2):109–117CrossRefPubMed
Metadata
Title
Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells
Authors
Michael W. Daniels
Guy N. Brock
James L. Wittliff
Publication date
01-01-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4049-8

Other articles of this Issue 2/2017

Breast Cancer Research and Treatment 2/2017 Go to the issue

Clinical trial

Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: Ten-year audit of single centre experience

Epidemiology

Pre-diagnostic breastfeeding, adiposity, and mortality among parous Hispanic and non-Hispanic white women with invasive breast cancer: the Breast Cancer Health Disparities Study

Epidemiology

Previous GWAS hits in relation to young-onset breast cancer

Epidemiology

Trends in cardiac mortality in women with ductal carcinoma in situ

Epidemiology

Differences in mammographic density between Asian and Caucasian populations: a comparative analysis

Rebuttal Letter

In reply to Kadri Altundag
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits